JPRN-jRCT2080223816已完成3 期
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome -Multi-center, Open-label, historical Control Comparative Study
FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)0 个研究点目标入组 30 人开始时间: 2018年2月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 84age old（—）
- 性别
- All
入选标准
- •1.Age:20 years old to less than 85 years old
- •2.Sex: No restriction
- •3.Outpatient/hospitalization: Hospitalization
- •4.Patients who are strongly suspected of SFTS
排除标准
- •1.Patients who have shown a trend toward improvement of symptoms.
- •2.Patients who are using ribavirin or has used ribavirin for this episode of infection
研究者
相似试验
进行中（未招募）
3 期
Phase III clinical trial of favipiravir in early-onset COVID-19 patients with severe risk factorsCOVID-19 patients with risk factors of progression to severe disease onset within 72 hours prior toJPRN-jRCT2041210004Sakurai Tsutomu316
招募中
3 期
The therapeutic effect of Favipiravir in COVID-19 patientsIRCT20211004052664N1Shahid Beheshti University of Medical Sciences80
已完成
不适用
The Real-world Clinical Outcomes of Favipiravir Treatment in Mild to Moderate COVID-19 Patients in Single Outpatient Visit Followed by Home Isolation: a Multicenter, case-control StudyTCTR20221113004Chulabhorn Royal Academy1,037
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
已完成
不适用
Clinical study of favipiravir for patients with severe fever with thrombocytopenia syndrome 2017severe fever with thrombocytopenia syndromeJPRN-UMIN000029020Ehime University Hospital10